Free Trial

Spyre Therapeutics (SYRE) Competitors

Spyre Therapeutics logo
$17.06 +0.48 (+2.90%)
Closing price 08/26/2025 04:00 PM Eastern
Extended Trading
$17.05 -0.01 (-0.06%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SYRE vs. ADMA, ZLAB, AKRO, TLX, PTCT, LNTH, APLS, MLTX, PTGX, and MIRM

Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include ADMA Biologics (ADMA), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Telix Pharmaceuticals (TLX), PTC Therapeutics (PTCT), Lantheus (LNTH), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

Spyre Therapeutics vs. Its Competitors

Spyre Therapeutics (NASDAQ:SYRE) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Spyre Therapeutics currently has a consensus price target of $53.40, suggesting a potential upside of 213.01%. ADMA Biologics has a consensus price target of $27.67, suggesting a potential upside of 61.79%. Given Spyre Therapeutics' higher possible upside, equities analysts clearly believe Spyre Therapeutics is more favorable than ADMA Biologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spyre Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29
ADMA Biologics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

Spyre Therapeutics has a beta of 2.82, meaning that its share price is 182% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.

ADMA Biologics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spyre Therapeutics$890K1,157.78-$208.02M-$3.40-5.02
ADMA Biologics$426.45M9.57$197.67M$0.8619.88

ADMA Biologics has a net margin of 44.06% compared to Spyre Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 41.01% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Spyre TherapeuticsN/A -71.30% -38.69%
ADMA Biologics 44.06%41.01%28.47%

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by insiders. Comparatively, 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ADMA Biologics had 7 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for ADMA Biologics and 2 mentions for Spyre Therapeutics. ADMA Biologics' average media sentiment score of 1.70 beat Spyre Therapeutics' score of 1.33 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Spyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADMA Biologics
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

ADMA Biologics beats Spyre Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Spyre Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYRE vs. The Competition

MetricSpyre TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.00B$3.07B$5.73B$9.74B
Dividend YieldN/A2.26%3.95%4.07%
P/E Ratio-5.0220.5230.3026.09
Price / Sales1,157.78354.12423.66106.24
Price / CashN/A44.2437.7259.08
Price / Book3.438.139.816.67
Net Income-$208.02M-$54.08M$3.27B$265.43M
7 Day Performance4.34%4.48%3.64%3.36%
1 Month Performance-4.10%3.64%3.82%0.39%
1 Year Performance-38.66%7.34%32.55%19.43%

Spyre Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SYRE
Spyre Therapeutics
2.8654 of 5 stars
$17.06
+2.9%
$53.40
+213.0%
-36.8%$1.00B$890K-5.0273News Coverage
Positive News
ADMA
ADMA Biologics
4.2713 of 5 stars
$17.63
+3.8%
$27.67
+56.9%
-2.1%$4.05B$474.17M20.50530Positive News
ZLAB
Zai Lab
2.3996 of 5 stars
$35.69
-0.1%
$57.22
+60.3%
+80.1%$3.97B$398.99M-17.501,869Analyst Forecast
AKRO
Akero Therapeutics
3.9862 of 5 stars
$48.59
-1.6%
$81.57
+67.9%
+76.0%$3.95BN/A-24.3030Positive News
TLX
Telix Pharmaceuticals
N/A$11.90
+3.1%
$22.33
+87.7%
N/A$3.91B$516.72M0.00N/AAnalyst Revision
High Trading Volume
PTCT
PTC Therapeutics
4.3331 of 5 stars
$49.80
+2.0%
$70.15
+40.9%
+41.7%$3.88B$1.76B7.141,410
LNTH
Lantheus
4.7626 of 5 stars
$55.97
+3.3%
$105.50
+88.5%
-48.1%$3.68B$1.52B14.89700Analyst Revision
APLS
Apellis Pharmaceuticals
4.1324 of 5 stars
$27.35
-1.4%
$34.12
+24.7%
-29.9%$3.50B$781.37M-15.03770
MLTX
MoonLake Immunotherapeutics
2.0184 of 5 stars
$53.73
-1.2%
$74.43
+38.5%
+13.2%$3.49BN/A-19.332
PTGX
Protagonist Therapeutics
1.898 of 5 stars
$56.21
+0.2%
$67.20
+19.6%
+37.0%$3.49B$434.43M80.30120News Coverage
Positive News
MIRM
Mirum Pharmaceuticals
3.6124 of 5 stars
$66.68
-1.8%
$74.13
+11.2%
+72.2%$3.41B$336.89M-55.11140Positive News
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:SYRE) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners